How to Improve Pancreatic Cancer Life Expectancy

How to Improve Pancreatic Cancer Life Expectancy

Pancreatic cancer is a disease that primarily affects the pancreas. The pancreas is mostly located in the interior parts below the abdomen and the stomach. The pancreas is essential because it releases enzymes to catalyze the digestion process, and also helps maintain blood sugar levels stable.

Sadly, pancreatic cancer is rarely detected, and an effective treatment can be difficult to find. The symptoms of pancreatic cancer are usually felt at the peak of the disease—which gives the patient very little time to find a treatment.

The life expectancy of individuals who are diagnosed with pancreatic cancer is usually about five to eight months. Albeit pancreatic cancer life expectancy is very low, it is still possible to prolong the life expectancy of pancreatic cancer. The following information below shows a detailed guide on how to increase pancreatic cancer life expectancy, and how to treat pancreatic cancer symptoms.

Read more at Suite101: How to Improve Pancreatic Cancer Life Expectancy http://cancer.suite101.com/article.cfm/how-to-improve-pancreatic-cancer-life-expectancy#ixzz0n2bUupVV

Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch

Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch

MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).

Posted using ShareThis

Pancreatic cancer - Wikipedia, the free encyclopedia

Pancreatic cancer - Wikipedia, the free encyclopedia

Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease.^[1] The prognosis is relatively poor but has improved; the three-year survival rate is now about thirty percent, but less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still rather rare.^[2]
About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells.^[3] Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.^[4][5]

Posted using ShareThis